Data gathered: April 27
AI Stock Analysis - Guardant Health (GH)
Analysis generated April 21, 2024. Powered by Chat GPT.
Guardant Health is a pioneer in the field of oncology-focused precision medicine. The company specializes in blood tests, data sets, and analytics offering a non-invasive approach to detect, monitor, and inform cancer treatment. Their leading product lines include the Guardant360 and GuardantOMNI tests, which are utilized for advanced stage cancer diagnosis and treatment decisions. By leveraging its proprietary digital sequencing technology, Guardant Health aims to contribute significantly to cancer care, fostering personalized treatment paths and aiding in the detection of early-stage cancers.
Stock Alerts - Guardant Health (GH)
 |
Guardant Health | April 23 Price is up by 7.3% in the last 24h. |
|
Guardant Health | April 19 Insider Alert: Tariq Musa is selling shares |
|
Guardant Health | April 10 Price is down by -6.5% in the last 24h. |
|
Guardant Health | April 9 Price is up by 7.8% in the last 24h. |
Alternative Data for Guardant Health
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 111 | Sign up | Sign up | Sign up |
| Sentiment | 83 | Sign up | Sign up | Sign up |
| Webpage traffic | 48,000 | Sign up | Sign up | Sign up |
| Employee Rating | 64 | Sign up | Sign up | Sign up |
| Google Trends | 41 | Sign up | Sign up | Sign up |
| Patents | 193 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 13 | Sign up | Sign up | Sign up |
| Facebook Followers | 1,241 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 14 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 4,664 | Sign up | Sign up | Sign up |
| Twitter Followers | 6,143 | Sign up | Sign up | Sign up |
| Twitter Mentions | 34 | Sign up | Sign up | Sign up |
| Youtube Subscribers | 611 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Lobbying Cost | $87,000 | Sign up | Sign up | Sign up |
| Business Outlook | 57 | Sign up | Sign up | Sign up |
| Linkedin Employees | 3,313 | Sign up | Sign up | Sign up |
About Guardant Health
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally.
| Price | $48.30 |
| Target Price | Sign up |
| Volume | 1,400,000 |
| Market Cap | $5.96B |
| Year Range | $20.2 - $49.94 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Earnings Date | April 30 '25 |
| Industry | Biotechnology |
In the news
 |
8,118 Shares in Guardant Health, Inc. (NASDAQ:GH) Acquired by Bank of Montreal CanApril 25 - ETF Daily News |
|
Analysts Offer Predictions for Guardant Health Q3 EarningsApril 25 - ETF Daily News |
|
LPL Financial LLC Decreases Stock Holdings in Guardant Health, Inc. (NASDAQ:GH)April 25 - ETF Daily News |
 |
Guardant Health, Pfizer Collaborate To Develop New Cancer Therapies Using Liquid Biopsy PlatformApril 24 - Yahoo |
|
Rockefeller Capital Management L.P. Boosts Position in Guardant Health, Inc. (NASDAQ:GH)April 24 - ETF Daily News |
|
Guardant Health Announces Strategic Collaboration With Pfizer to Support Development and Commercialization of New Cancer Therapies Using Guardant Infinity Smart Liquid Biopsy PlatformApril 23 - Yahoo |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 191M | 148M | 44M | -108M | -107M | -0.880 |
| Q2 '24 | 177M | 123M | 54M | -103M | -101M | -0.840 |
| Q1 '24 | 168M | 120M | 49M | -115M | -113M | -0.940 |
| Q4 '23 | 155M | 117M | 38M | -187M | -186M | -0.850 |
| Q3 '23 | 143M | 106M | 37M | -86M | -84M | -0.730 |
Insider Transactions View All
| Tariq Musa filed to sell 3,345 shares at $44.8. April 18 '25 |
| Tariq Musa filed to sell 3,211 shares at $43.7. March 20 '25 |
| Kalia Kumud filed to sell 19,720 shares at $43.2. March 18 '25 |
| Joyce Meghan V. filed to sell 7,647 shares at $42.7. March 5 '25 |
| Tariq Musa filed to sell 3,078 shares at $48.3. February 21 '25 |
Similar companies
Read more about Guardant Health (GH) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, youtube subscribers, news mentions, customer reviews, lobbying cost, business outlook & linkedin employees.
What is the Market Cap of Guardant Health?
The Market Cap of Guardant Health is $5.96B.
When does Guardant Health report earnings?
Guardant Health will report its next earnings on April 30 '25.
What is the current stock price of Guardant Health?
Currently, the price of one share of Guardant Health stock is $48.30.
How can I analyze the GH stock price chart for investment decisions?
The GH stock price chart above provides a comprehensive visual representation of Guardant Health's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Guardant Health shares. Our platform offers an up-to-date GH stock price chart, along with technical data analysis and alternative data insights.
Does GH offer dividends to its shareholders?
As of our latest update, Guardant Health (GH) does not offer dividends to its shareholders. Investors interested in Guardant Health should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Guardant Health?
Some of the similar stocks of Guardant Health are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.